The nation of Zimbabwe has rejected a significant US healthcare agreement worth 367 million US dollars (£272m) spanning five years because of Washington's request for confidential information.
This move came to light after a official document dated December was leaked, which showed Head of State Emmerson Mnangagwa felt the deal was "skewed".
A government representative has since explained that the US was demanding access to biological samples for research and commercial gain but refused to guarantee the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable task of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had donated over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged further talks to reach a deal agreeable to all parties so the country's vital HIV treatment initiative can be sustained.
Wider Background
This development follows a comparable situation in Kenya, where a high court blocked a similar health funding agreement following concerns were filed about the safety of citizens' medical information.
After returning to office last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had administered assistance for the US government, but Trump claimed its expenditure was "inefficient" and his government was pursuing direct bilateral deals to boost transparency and responsibility.
Based on reports, 16 nations in Africa have so far agreed to similar health pacts, constituting more than $18.3bn in new funding.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership would have delivered extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy through American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, without any corresponding assurance of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"Put simply, our country would provide the basic resources for scientific discovery with no certainty that the resulting innovations would be available to our population should a future health crisis emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining frameworks previously set up via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing system created to deal with potential global health emergencies.
"This framework is intended to ensure that when a country provides its samples, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," he added.
"We encourage ongoing dialogue with our American counterparts on how future co-operation might be arranged in a manner that honours the sovereignty and interests of each country."
Health Experts Response
A leading public health body expressed it acknowledged the government's concerns, but suggested that negotiations should continue since a large portion of the country's HIV programmes depended on international support.
"Where technical issues arise, including those involving data governance or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," the group added.
The halted deal highlights the continuing debate between receiving vital international aid and protecting local interests in an ever more data-driven world.